Celularity Inc. Form 8-K Summary
Business Context and Reporting Period
Celularity Inc. filed a Form 8-K reporting a management appointment and related compensation arrangements. The earliest reported event was September 9, 2021; the employment agreement and filing signature are dated September 15, 2021. No quarterly or annual financial results were reported.
Key Financial and Corporate Matters
- Andrew L. Pecora, M.D. was appointed President effective September 15, 2021, replacing Robert J. Hariri, M.D., Ph.D.
- Dr. Hariri remains Chief Executive Officer and Chairman of the Board.
- Dr. Pecora’s initial annual base salary is $900,000.
- Beginning in 2022, he is eligible for a discretionary annual bonus targeted at 60% of base salary, subject to individual and company performance goals.
- He received a one-time front-loaded equity award covering 2,469,282 shares of Class A common stock, vesting in up to five installments based on share-price targets between the third and fourth anniversaries of employment, subject to continued service.
- He received a $1.2 million signing bonus payable in four annual installments of $300,000. Amounts are generally subject to repayment, with prorated forgiveness, if employment ends before the applicable installment is earned.
- The filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or other operating financial metrics.
Material Changes and Unusual Items
- The appointment separates the President role from the CEO role, with Dr. Hariri continuing as CEO and Chairman.
- Dr. Pecora’s employment agreement provides severance upon qualifying termination without cause or resignation for good reason, including nine months of salary and benefits outside a change in control and 12 months of salary and benefits in specified change-in-control circumstances.
- Change-in-control benefits may include a prorated or full annual bonus and accelerated equity vesting, subject to the agreement’s conditions and share-price provisions.
- Dr. Pecora also received an option to purchase 153,718 shares at an exercise price of $10.23 per share; 50% was vested at grant, with the balance subject to time-based vesting through the fourth anniversary of the business combination.
- Previously assumed or granted options provide additional rights to acquire shares at exercise prices of $0.28, $3.70, $3.83, and $10.21 per share.
Related-Party Disclosures and Risks
- Dr. Pecora previously served as a director, consultant, and scientific advisor to Celularity Operations, Inc. He received prior cash compensation, bonuses, and equity awards.
- Celularity has a data-license arrangement with COTA, Inc., where Dr. Pecora is founder and chairman and director Robin L. Smith is an investor. The filing identifies this as a related-party relationship.
- Dr. Pecora’s son, Matthew Pecora, was previously employed by Celularity Operations, Inc. and received compensation and equity awards on terms generally applicable to comparable employees.
- Material obligations include potential salary continuation, benefit coverage, bonus payments, equity acceleration, signing-bonus repayment provisions, and tax-related limitations under Internal Revenue Code Section 4999.
Investor Verification Checklist
- Review Exhibit 10.1 for the complete employment agreement, vesting conditions, termination definitions, and severance calculations.
- Verify the effective dates, because the filing identifies September 9 as the earliest event date while the agreement and signature are dated September 15, 2021.
- Assess the potential dilution from the 2,469,282-share front-loaded award and other outstanding options.
- Review subsequent filings for changes in Dr. Pecora’s role, compensation, employment status, or equity vesting.
- Review related-party disclosures regarding COTA and any continuing consulting, data-license, or family-employment arrangements.